Lttl NAD+ Review: $129 on Every Card, $199 on the Ladder

Most companies on our NAD+ board hide their pricing behind an intake quiz. Lttl does the opposite, and does it better than anyone else we rank: the complete pricing object — fourteen products, seventy plan rows, every term rung, each one labelled with what it actually bills — ships in the public source of [lttl.com/plans](https://lttl.com/plans) before you have typed anything. You can read the whole commercial structure of the business in an afternoon.

Which is how we know the number on its product cards is wrong.

Every one of Lttl's fourteen product cards carries the same hardcoded string: from $129/mo. Not computed — typed. For NAD+, $129 is the twelve-month rung, billed $1,548 up front; the month-to-month rate is $199, and Lttl's own data says so in the same file, labelling that rung "$199/mo every month." For methylene blue, glutathione, MIC B12 and L-carnitine, whose ladders top out at $119, the $129 on the card is more than Lttl has ever charged for them. The card is not quoting you a cheap tier. It is not quoting you anything.

What Lttl is

Lttl is prescription telehealth operated by The Commerce Group Holdings, LLC, named in its terms of service. It runs three lanes, and its landing page presents them as co-equal cards: weight loss, longevity, and a microdose GLP-1 tier. The H1 is "GLP-1 Weight Loss, Longevity & Microdose Care Done a Lttl Differently."

That balance matters for whether it belongs on this site at all, and we checked it rather than assuming. Of the fourteen products in the catalogue, eight are the longevity shelf — NAD+ as an injection, a nasal spray and an oral liposomal liquid, plus sermorelin, glutathione, MIC B12, L-carnitine and oral methylene blue. Three are GLP-1 weight loss and three are the microdose tier. NAD+ is not a bolt-on here; it is the anchor of the larger half of the catalogue, and it is sold on exactly the thing this site is about. The NAD+ page is headed "NAD+ Injections: Boost Energy & Focus," and promises to "Boost clarity, concentration, and recall so you can think faster, stay on task, and perform at your best." Its testimonials are about afternoon crashes and brain fog.

Terms of service put coverage at all fifty states plus Washington D.C., with the caveat that "some services may not be available in all 50 states." Billing is month-to-month — "No contracts · Free shipping · Cancel anytime" — and the clinician consult is inside the price. In a category where Shed sets a two-month minimum in section eleven of its terms, that is worth stating plainly.

The ladder is exemplary. The card on top of it is not.

Take the good part first, because it is genuinely rare. Here is Lttl's NAD+ ladder, identical across all three routes:

$199 month-to-month. $169 on three months. $149 on six. $129 on twelve, billed $1,548 at once. A first-month special of $149 runs against a $229 struck-through rate.

Every one of those rungs is published with its billing terms attached. Nobody else on our board does this. Wellorithm publishes $200 and then footnotes it into a three-month prepay. MyDrHank advertises a figure computed at runtime that its catalogue cannot produce, which we took apart separately. Lttl hands you the whole table.

And then puts "from $129/mo" on the card.

For NAD+ that is the ordinary prepay trap: the cheapest rung, advertised as though it were the monthly rate, with the $1,548 commitment unmentioned. A reader comparing Lttl's "$129" against our #1 pick's genuinely month-to-month $93 is comparing an annual prepay against a monthly bill.

The reason we can be certain it is a typed string rather than a computed minimum is what happens on the rest of the shelf. We enumerated all fourteen products against their own ladders:

• •Semaglutide injectable, NAD+ (all three routes), sermorelin — $129 is the twelve-month rung. Real, but a prepay.
• •Microdose semaglutide and tirzepatide injectables — $129 is the three-month rung.
• •Tirzepatide injectable — the ladder runs $279 / $249 / $229 / $199. $129 is purchasable at no tier.
• •Semaglutide ODT ($229–$159) and microdose ODT ($179–$139) — $129 at no tier.
• •Methylene blue, glutathione, MIC B12, L-carnitine — the ladder runs $119 / $99 / $89 / $79. $129 is above the most expensive rate Lttl charges.

Seven of fourteen products advertise a price that cannot be bought. Four of those are advertised at a price higher than the worst rate on offer. No minimum function produces that — a `min()` over tirzepatide returns $199, over methylene blue $79. The number was typed once and pasted fourteen times.

It is a small thing done carelessly rather than a deception with a beneficiary — a company running a scam does not overcharge itself on its own advertising. But it lands on the reader the same way, and it is the single most checkable fact about this company.

What it publishes that almost nobody else will

Two things here are better than the board average, and both are the kind of disclosure that makes a price comparable rather than decorative.

It publishes a dose. The NAD+ page states "500mg-1000mg injections available" and the FAQ adds that "most patients begin at 100mg and adjust over the first few weeks based on response." Lttl also advertises "Same Price, Every Dose." Set that against the rest of our board: Willow's $199 is a flat published rate for an injection whose vial strength is never stated, and Shed's figures all read "starting at" with no strength anywhere. A price without a dose cannot be turned into a cost per milligram, which means it cannot really be compared at all. Lttl's can.

It has no minimum term. Month-to-month, cancel anytime, consult included. The competitor immediately above it on our board requires two months of every program before you may cancel.

Both of those are real, and together they are why Lttl ranks where it does rather than lower.

The evidence: "scientifically proven," citing nothing

Under a badge reading "Compounded By U.S.A. Licensed Pharmacies," Lttl's NAD+ page says this: "Scientifically proven to help you feel younger, sharper, and more alive."

There is not one citation on the page. No trial, no footnote, no reference list, no PMID — we checked the source, and the count is zero.

"Scientifically proven" is a stronger construction than anything else we have found in this category, and the distinction is worth drawing carefully. Shed's NAD+ page asserts benefits without citing anything, which is weak but honest about being an assertion. MyDrHank footnotes its headline to a real randomised trial that measured no cognitive endpoint — a citation that does not support the claim, borrowing authority it has not earned. Lttl claims the authority outright and then offers nothing at all. It is the only page on our board that uses the word "proven."

The FAQ goes further still. Asked "Can NAD+ help prevent Alzheimer's disease?", the page answers that "early research suggests NAD+ may support brain health by reducing neuroinflammation and supporting mitochondrial function in neurons," and that "while it is not a cure or approved treatment for Alzheimer's, preliminary studies show promise." The hedge is real and we credit it. But the question was put on the page by the company, not by a patient, and raising dementia prevention beside a checkout button sets an expectation no evidence supports.

Here is what the trials actually show, and it is the same position this site applies to every provider on every board: no rigorous human trial shows that nasal, injected or oral NAD+ improves cognition or energy. The best available results run against the claim. In older adults with mild cognitive impairment, oral nicotinamide riboside raised NAD+ levels and did not improve cognition versus placebo¹. A second randomised trial in subjective cognitive decline and MCI likewise found no cognitive benefit². The only human data on a parenteral route is a pilot that tracked NAD+ metabolites through a six-hour infusion and measured no cognitive outcome whatsoever³. The full picture is in our NAD+ brain fog and focus evidence review, and the precursor literature specifically in what the NMN and NR trials actually found.

The page also runs a comparison table against retail supplements claiming "~100% bioavailability (injection)" versus "Low: 1–15% absorbed only," and promises effects "Fast - feel energy & clarity in days." Higher bioavailability than an oral supplement is pharmacologically unremarkable and probably true. It is not evidence that either one does anything for focus, which is the claim the table is positioned under.

What it will not tell you

Which pharmacy. Lttl says all medications "are compounded by 503A and 503B licensed pharmacies that operate under FDA oversight" and that "every batch is tested for purity, potency, and sterility." No pharmacy is named anywhere on the site. "503A and 503B" describes a category of facility, not a supplier, and the company states plainly elsewhere that it "does not manufacture medications."

What "FDA oversight" covers. Its own footer is more careful than its FAQ: "Compounded medications offered through Lttl are produced in FDA-registered facilities but are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality." Both sentences are on the same site. The second is the accurate one, and it is the one in the small print.

Which services are missing where. Coverage is given as all fifty states plus D.C., immediately qualified by "some services may not be available in all 50 states." Which services, and which states, is not published.

Who the clinicians are. Lttl says every patient is reviewed by "a licensed physician in their state." No physician is named, and no medical director is identified — a contrast with several rows on our board that name a prescriber outright.

Who it is for, and who it is not

If you want NAD+ without a needle and without a nasal spray, Lttl is one of the few clinician-supervised routes to an oral liposomal liquid, and the price is the same as the injection. If you want a provider that will tell you how many milligrams you are buying, it is one of the very few that publishes a dose range and charges the same at every dose — which makes $199 a number you can actually compare.

If you are shopping on price alone, note that $199 is mid-field on our board of NAD+ providers ranked on published price and roughly double the top of it, and that the $129 you may have seen advertised requires $1,548 in one payment. If it is the injection specifically you are pricing, the NAD+ injection comparison puts Lttl's $199 beside every other injectable we could price.

And if you are here because your thinking feels slow and you are hoping a prescription will fix it, read what actually causes brain fog before spending anything. Sleep debt, thyroid, iron, B12, alcohol and ordinary medication side effects account for far more foggy thinking than a coenzyme does, and every one of them is cheaper to rule out than $199 a month.

The bottom line

Lttl is an enforcement-clean prescription telehealth company that names its operating entity, sells NAD+ in three routes including a swallowed one, publishes a real dose range, charges the same at every dose, and — genuinely to its credit — puts its entire price ladder in public with the billing terms attached to every rung. We screened the FDA's warning-letter database on 7 August 2026 and found nothing against it.

It then prints a single hardcoded "$129/mo" across all fourteen of its product cards: a twelve-month prepay rung for the product you came for, a price that exists at no tier for three others, and a figure higher than it has ever charged for four more. And it sells a coenzyme as "scientifically proven" to make you sharper while citing nothing, on a page that raises Alzheimer's prevention unprompted. The month-to-month price is $199, it is published, and it is the number we file.